{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T05:10:20Z","timestamp":1791868220176,"version":"4.3.4"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>Based on cross-sectional and follow-up data, we aimed to explore the continuous long-term pattern of beta-cell function change in type 2 diabetes and to analyze the relevant influencing factors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>Data from 2898 type 2 diabetic subjects were retrospectively analyzed. Islet beta-cell function was evaluated by the homeostasis model assessed index (HOMA-\u03b2). The pattern of association between HOMA-\u03b2 and disease duration coverup of 50 years were explored using non-linear regression approaches. Findings were replicated in longitudinal follow-up data from multi-centers. Influencing factors of both residual HOMA-\u03b2 level and HOMA-\u03b2 decline rate were investigated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We identified a model including three clear phases of HOMA-\u03b2 change: an initial ascending phase over 4.2 years from diagnosis (3.34% change per year [95%CI 0.04, 6.52]), followed by a phase of exponential fall up to 20.9 years from diagnosis (-3.04% change per year [95%CI -3.78, -2.29]) and thereafter a low and plateau phase (0.17% change per year [95% CI -0.72, 1.05]). Longitudinal follow-up data verified this model. Higher BMI (OR = 1.103 [95%CI 1.047, 1.161]), UA (OR = 1.003 [95%CI 1.001, 1.005]), metabolic Syndrome (OR = 1.526 [95%CI 1.021, 2.279]) and lower HbA1c (OR = 0.695 [95%CI 0.627, 0.771]) levels were independently associated with higher residual HOMA-\u03b2 level. Earlier diagnosis (Coefficient=0.0009 [95%CI 0.0002, 0.0016]) was independently associated with faster HOMA-\u03b2 decline.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Beta-cell function change in the course of type 2 diabetes was nonlinear with multi-phases. Targeting the factors that affect different phases would contribute to the protection of the disease progression.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2025.1602796","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T04:20:41Z","timestamp":1760070041000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Multi-phases of islet beta-cell function change in type 2 diabetes mellitus and its influencing factors"],"prefix":"10.3389","volume":"16","author":[{"given":"Jin","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01655-5","article-title":"Type 2 diabetes","volume":"400","author":"Ahmad","year":"2022","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.25.2.330","article-title":"Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57)","volume":"25","author":"Wright","year":"2002","journal-title":"Diabetes Care"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-1353","article-title":"CRP, C-peptide, and risk of first-time cardiovascular events and mortality in early type 2 diabetes: A Danish cohort study","volume":"46","author":"Gedebjerg","year":"2023","journal-title":"Diabetes Care"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15409","article-title":"Glycated hemoglobin, HOMA2-B, C-peptide to glucose ratio and type 2 diabetes clusters as predictors for therapy failure in individuals with type 2 diabetes without insulin therapy: A registry analysis","volume":"26","author":"Aziz","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/bf00273856","article-title":"Hyperglycemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: implications for the management of diabetes","volume":"28","author":"Unger","year":"1985","journal-title":"Diabetologia"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s005920070014","article-title":"Relationship of residual beta-cell function, metabolic control and chronic complications in type 2 diabetes mellitus","volume":"37","author":"Bo","year":"2000","journal-title":"Acta Diabetol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.110568","article-title":"Clinical expert consensus on the assessment and protection of pancreatic islet \u03b2-cell function in type 2 diabetes mellitus","volume":"197","author":"Zhu","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcg040","article-title":"Deteriorating beta-cell function in type 2 diabetes: a long-term model","volume":"96","author":"Bagust","year":"2003","journal-title":"QJM"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2337\/db10-1392","article-title":"Effects of rosiglitazone, glyburide, and metformin on \u03b2-cell function and insulin sensitivity in ADOPT","volume":"60","author":"Kahn","year":"2011","journal-title":"Diabetes"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2011.10.003","article-title":"The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial","volume":"25","author":"Duckworth","year":"2011","journal-title":"J Diabetes Complications"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-024-09914-9","article-title":"Clinical research progress on \u03b2-cell dysfunction in T2DM development in the Chinese population","volume":"26","author":"Chen","year":"2024","journal-title":"Rev Endocr Metab Disord"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m997","article-title":"Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study","volume":"369","author":"Li","year":"2020","journal-title":"BMJ"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1096-9136(199807)15:7%3C539::aid-dia668%3E3.0.co;2-s","article-title":"Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation","volume":"15","author":"Alberti","year":"1998","journal-title":"Diabetes Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S002","article-title":"Diagnosis and classification of diabetes: standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2000.00335.x","article-title":"Serum C-peptide concentrations poorly phenotype type 2 diabetic end-stage renal disease patients","volume":"58","author":"Covic","year":"2000","journal-title":"Kidney Int"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.12847","article-title":"Metabolic Management Center: An innovation project for the management of metabolic diseases and complications in China","volume":"11","author":"Zhang","year":"2019","journal-title":"J Diabetes"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn115791-20220104-00005","article-title":"Expert consensus on the assessment and protection of pancreatic islet \u03b2\u2212cell function in patients with type 2 diabetes mellitus","volume":"14","year":"2022","journal-title":"Chin J Diabetes Mellitus"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3760\/cma.j.issn.1674-5809.2018.01.003","article-title":"Guidelines for prevention and treatment of type 2 diabetes in Chinese (2017 edition)","volume":"10","year":"2018","journal-title":"Chin J Diabetes Mellitus"},{"key":"B19","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/s2213-8587(21)00047-4","article-title":"Clinical management and treatment of obesity in China","volume":"9","author":"Zeng","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.11.2597","article-title":"Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function","volume":"27","author":"Li","year":"2004","journal-title":"Diabetes Care"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2337\/db19-0299","article-title":"Effects of treatment of impaired glucose tolerance or recently diagnosed type 2 diabetes with metformin alone or in combination with insulin glargine on \u03b2-cell function: comparison of responses in youth and adults","volume":"68","year":"2019","journal-title":"Diabetes"},{"key":"B22","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s00125-021-05577-2","article-title":"Diets for weight management in adults with type 2 diabetes: an umbrella review of published meta-analyses and systematic review of trials of diets for diabetes remission","volume":"65","author":"Churuangsuk","year":"2022","journal-title":"Diabetologia"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn115791-20200403-00185","article-title":"Analysis of islet beta cell function assessed by C-peptide changing with the disease duration in patients with type 2 diabetes mellitus","volume":"12","author":"Yu","year":"2020","journal-title":"Chin J Diabetes Mellitus"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2020.1771047","article-title":"Beta-cell failure in type 2 diabetes: mechanisms, markers, and clinical implications","volume":"132","author":"Wysham","year":"2020","journal-title":"Postgrad Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41392-024-01951-9","article-title":"Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy","volume":"9","author":"Lu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-er07a","article-title":"Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-011-2204-7","article-title":"Reversal of type 2 diabetes: normalization of beta cell function in association with decreased pancreas and liver triacylglycerol","volume":"54","author":"Lim","year":"2011","journal-title":"Diabetologia"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0575","article-title":"Determinants of diabetes remission and glycemic control after bariatric surgery","volume":"39","author":"Panunzi","year":"2016","journal-title":"Diabetes Care"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1006\/jtbi.2000.2150","article-title":"A model of beta-cell mass, insulin, and glucose kinetics: pathways to diabetes","volume":"206","author":"Topp","year":"2000","journal-title":"J Theor Biol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2337\/db23-0966","article-title":"Comparison of \u03b2-cell function and insulin sensitivity between normal-weight and obese Chinese with young-onset type 2 diabetes","volume":"73","author":"Fan","year":"2024","journal-title":"Diabetes"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e3001","DOI":"10.1002\/dmrr.3001","article-title":"Serum uric acid to creatinine ratio correlates with \u03b2-cell function in type 2 diabetes","volume":"34","author":"Li","year":"2018","journal-title":"Diabetes Metab Res Rev"},{"key":"B32","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12902-021-00698-6","article-title":"Uric acid-induced pancreatic \u03b2-cell dysfunction","volume":"21","author":"Ghasemi","year":"2021","journal-title":"BMC Endocr Disord"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2013.00052","article-title":"Mechanisms of obesity-induced inflammation and insulin resistance: insights into the emerging role of nutritional strategies","volume":"4","author":"McArdle","year":"2013","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-s008","article-title":"Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes-2024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2013.0081","article-title":"Clinical evidence for the earlier initiation of insulin therapy in type 2 diabetes","volume":"15","author":"Owens","year":"2013","journal-title":"Diabetes Technol Ther"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22157917","article-title":"Favorable effects of GLP-1 receptor agonist against pancreatic \u03b2-cell glucose toxicity and the development of arteriosclerosis: \u201cThe earlier, the better\u201d in therapy with incretin-based medicine","volume":"22","author":"Kaneto","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23095104","article-title":"Effects of sodium-glucose co-transporter-2 inhibitors on pancreatic \u03b2-cell mass and function","volume":"23","author":"Nakamura","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2018.01.019","article-title":"DPP-4 is expressed in human pancreatic beta cells and its direct inhibition improves beta cell function and survival in type 2 diabetes","volume":"473","author":"Bugliani","year":"2018","journal-title":"Mol Cell Endocrinol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0991","article-title":"An inverse relationship between age of type 2 diabetes onset and complication risk and mortality: the impact of youth-onset type 2 diabetes","volume":"39","author":"Al-Saeed","year":"2016","journal-title":"Diabetes Care"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.110954","article-title":"Comparison of beta-cell function between Hong Kong Chinese with young-onset type 2 diabetes and late-onset type 2 diabetes","volume":"205","author":"Fan","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.2337\/db20-0443","article-title":"Erratum. The first genome-wide association study for type 2 diabetes in youth: the progress in diabetes genetics in youth (ProDiGY) consortium. Diabetes 2021;70:996-1005","volume":"70","author":"Srinivasan","year":"2022","journal-title":"Diabetes"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.2147\/nss.s413992","article-title":"Association of bedtime with early-onset diabetes and islet beta cell function in patients with newly diagnosed type 2 diabetes mellitus","volume":"15","author":"Ma","year":"2023","journal-title":"Nat Sci Sleep"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.2174\/1573399814666180608074510","article-title":"Pathophysiology of type 2 diabetes in children and adolescents","volume":"16","author":"Valaiyapathi","year":"2020","journal-title":"Curr Diabetes Rev"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-2834","article-title":"Latent autoimmune diabetes of adults (LADA) is likely to represent a mixed population of autoimmune (Type 1) and nonautoimmune (Type 2) diabetes","volume":"44","author":"Jones","year":"2021","journal-title":"Diabetes Care"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.6.1487","article-title":"Use and abuse of HOMA modeling","volume":"27","author":"Wallace","year":"2004","journal-title":"Diabetes Care"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1602796\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T04:20:43Z","timestamp":1760070043000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1602796\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":46,"alternative-id":["10.3389\/fendo.2025.1602796"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1602796","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"article-number":"1602796"}}